Biosimilar Development News

  1. Chipscreen Biosciences Announces A Collaboration With Innovent To Evaluate Chidamide And The Combination Of Sintilimab, Anti-VEGF Monoclonal Antibody IBI305 In Colorectal Cancer Patients
    2/17/2019

    Chipscreen Biosciences, a leading integrated Chinese biotech company specialized in discovery and development of novel small molecule pharmaceuticals with a primary focus in oncology, metabolic disease, and autoimmune diseases, announce the signing of a collaboration agreement with Innovent Biologics, Inc. (Innovent) to evaluate the safety and tolerability of Chipscreen's Chidamide and Innovent's Sintilimab in combination with an anti-VEGF monoclonal antibody IBI305 in patients with advanced colorectal carcinoma.

  2. Global Interferons Market 2019-2023 | Advent Of Biosimilars To Boost Growth | Technavio
    2/13/2019

    The global interferons market is expected to post a CAGR of close to 2% during the period 2019-2023, according to the latest market research report by Technavio.

  3. The Biosimilars Forum Objects To Consolidate Billing Of Biosimilars
    2/12/2019

    “A separate coding and payment policy for biosimilars could offer greater savings to the Medicare program, as well as encourage greater price competition and uptake of biosimilar products in the marketplace. Ultimately, patients would benefit the most from a payment policy that enhances access, achieves long-term savings, and supports a competitive marketplace.”

  4. C-Bridge Capital Forms AffaMed Therapeutics To Accelerate Commercialization Of Biologics In China
    2/11/2019

    AffaMed Therapeutics, a new biopharmaceutical company founded and funded by C-Bridge Capital, a healthcare private equity firm focused on the development and late-stage investment opportunities, announced today that it is partnering with Samsung Bioepis to accelerate the commercialization of multiple next-generation biosimilars in China. Pharmaceutical industry veteran, Dr. Nathan Pang, will lead the Company as CEO.

  5. Samsung Bioepis And C-Bridge Capital To Develop And Commercialize Next-Generation Biosimilars In China
    2/10/2019

    Samsung Bioepis Co., Ltd. recently announced its expansion in mainland China through a licensing agreement with C-Bridge Capital.

  6. Mundipharma Launches Pelmeg (Pegfilgrastim) Biosimilar In Europe
    2/5/2019

    The Mundipharma network of independent associated companies recently announced the launch of Pelmeg (pegfilgrastim), a biosimilar of Neulasta following European Commission (EC) approval in November 2018.

  7. Paras Biopharmaceuticals Finland Oy Announces Successful Development Of Biologically Active Romiplostim (N-Plate Biosimilar) Production Technology
    2/1/2019

    Paras Biopharmaceuticals Finland Oy recently announced the achievement of a major milestone – the successful development of biologically active Romiplostim (N-Plate biosimilar) production technology.

  8. Fresenius Kabi Receives Positive CHMP Opinion For MSB11022, A Biosimilar Candidate Of Adalimumab
    2/1/2019

    Fresenius Kabi announced recently that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion, recommending marketing authorization for MSB11022, a biosimilar candidate of Humira (adalimumab).

  9. CrowdReviews Partnered With IMAPAC Pte. Ltd. To Announce: 8th Annual Biologics Manufacturing Korea 2019
    1/31/2019

    Beyond K-pop and K-food, K-biologics is set to increase in popularity. According to Reports, Korea’s “bio fever” is being spurred on by the domestic development of biosimilars by firms such as Celltrion, Samsung Bioepis, LG Chem, GC Green Cross, Chong Kun Dang, CJ Healthcare, and Dong-A ST.

  10. The Biosimilars Forum Applauds HHS Proposal To Target Costly Rebates Structure Blocking Patients From Biosimilars And Savings
    1/31/2019

    The Biosimilars Forum applauded today’s proposed HHS rule attacking negotiated rebates between manufacturers and insurers.